Natco Pharma Reports Multifold Rise In Consolidated Net Profit To Rs 320.4 Cr

The company had posted a consolidated net profit of Rs 75 crore in the same period last fiscal,

Natco Pharma Signs Agreement With MPP To Sell Molnupiravir Capsules

Natco Pharma Ltd said it has signed a non-exclusive license agreement with the Medicines Patent Pool (MPP), Switzerland to manufacture and sell Molnupiravir capsules 200 mg for treatment of COVID-19.

Natco Pharma's Marketing Partner Gets USFDA Nod For Anti-Cancer Drug

Natco Pharma said based on the ANDA filing date, the company believes that it is eligible for 180 days of sole generic marketing exclusivity for the 10 mg strength and shared 180 days of generic marketing exclusivity for the 60 mg strength of the product at the time of launch.

Natco Pharma Initiates Molnupiravir Phase 3 Trials

Patients treated with Molnupiravir achieved response within five days of therapy, indicating that the duration of treatment with Molnupiravir is short, with the additional advantage of being an oral therapy

Natco Seeks CDSCO Approval For Phase-III Trial Of Molnupiravir For COVID-19 Treatment

Natco Pharma has applied to the Central Drugs Standard Control Organization (CDSCO) in India for approval of phase-III clinical trial of Molnupiravir capsules for the treatment of COVID-19 positive patients

Natco Pharma Board Okays Acquiring 1% In Canadian Arm

Stocks of Natco Pharma were trading 0.74 per cent lower at Rs 810.85 apiece on BSE.

Natco's Marketing Partner Gets USFDA Nod For Cancer Treatment Drug

Natco's partner BPI plans to launch 2.5 mg, 5 mg and 7.5 mg strengths of the product shortly within the next few weeks.

Natco Pharma Q3 Net Profit Declines 39 % To Rs 63 Cr

The consolidated total income of the company stood at Rs 386 crore for the quarter under consideration. It was Rs 513 crore for the same period a year ago

Natco Pharma Gets Registration Approval From CIB&RC For Chlorantraniliprole

CTPR is an active ingredient used in products commercialised by US-based chemicals maker FMC under brands Coragen and Ferterra.

Natco Pharma Q2 Net Profit Up 73% To Rs 204 Cr

The company had posted a net profit of Rs 117.7 crore for the corresponding period of the previous fiscal, Natco Pharma said in a BSE filing.

US Patent Ruling On Teva's Copaxone A Big Win For India

US Patent and Trade Mark Office’s decision to reject the patent claims of Teva Pharmaceutical Industries on its 40-milligram dosage of multiple sclerosis drug Copaxone is undoubtedly a booster dose for the generic drug industry and the Indian drug makers in particular

Natco Pharma, Gilead In Deal On Hepatitis C Drugs

India Rejects US Firm's Hepatitis C Drug Patent Request

Nexavar: HC Rules In Favour Of Natco Pharma

The Low-cost Argument